Search research articles
Contact Us
Filters
Showing results (231-240 of 277) with videos related to
Page
of 28
Sort By:
Journal of the National Cancer Institute
|
July 5, 2022
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab
Francesca Ligorio, Serena Di Cosimo, Paolo Verderio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2020
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Margaret L Axelrod, Mellissa J Nixon, Paula I Gonzalez-Ericsson, et al.
Nature Communications
|
December 11, 2020
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells
Clara Gómez-Aleza, Bastien Nguyen, Guillermo Yoldi, et al.
Nature Communications
|
November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Nature Communications
|
December 12, 2023
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Cancers
|
October 13, 2021
Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group
Mieke R Van Bockstal, Maxine Cooks, Iris Nederlof, et al.
Nature
|
November 7, 2024
Origins and impact of extrachromosomal DNA
Chris Bailey, Oriol Pich, Kerstin Thol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2020
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)
Priyanka Sharma, Bruce F Kimler, Anne O'Dea, et al.
NPJ Breast Cancer
|
May 22, 2020
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
Jan Hudeček, Leonie Voorwerk, Maartje van Seijen, et al.
Nature Cancer
|
April 10, 2023
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
Leonie Voorwerk, Olga I Isaeva, Hugo M Horlings, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 277) with videos related to
Sort By:
Page
of 28
Journal of the National Cancer Institute
|
July 5, 2022
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab
Francesca Ligorio, Serena Di Cosimo, Paolo Verderio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2020
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Margaret L Axelrod, Mellissa J Nixon, Paula I Gonzalez-Ericsson, et al.
Nature Communications
|
December 11, 2020
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells
Clara Gómez-Aleza, Bastien Nguyen, Guillermo Yoldi, et al.
Nature Communications
|
November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Nature Communications
|
December 12, 2023
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Cancers
|
October 13, 2021
Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group
Mieke R Van Bockstal, Maxine Cooks, Iris Nederlof, et al.
Nature
|
November 7, 2024
Origins and impact of extrachromosomal DNA
Chris Bailey, Oriol Pich, Kerstin Thol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2020
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)
Priyanka Sharma, Bruce F Kimler, Anne O'Dea, et al.
NPJ Breast Cancer
|
May 22, 2020
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
Jan Hudeček, Leonie Voorwerk, Maartje van Seijen, et al.
Nature Cancer
|
April 10, 2023
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
Leonie Voorwerk, Olga I Isaeva, Hugo M Horlings, et al.
Page
of 28